Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 13;13(16):4752.
doi: 10.3390/jcm13164752.

Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice

Paola Pantanetti  1 , Vanessa Ronconi  2 , Marco Sguanci  3 , Sara Morales Palomares  4 , Stefano Mancin  5 , Francesco Carlo Tartaglia  6 , Giovanni Cangelosi  1 , Fabio Petrelli  7
Affiliations

Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice

Paola Pantanetti et al. J Clin Med. .

Abstract

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of incretin mimetics for treating type 2 diabetes (T2D). This study evaluated the impact of semaglutide, the first oral GLP-1RA, on glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and body composition and anthropometric parameters. Additionally, the effects on cardiovascular risk factors and quality of life (QoL) in T2D patients were assessed. Methods: A prospective observational study with a six-month follow-up was conducted. Clinical parameters, including HbA1c, FPG, anthropometric measurements, blood pressure, cardiovascular risk factors, Diabetes Treatment Satisfaction Questionnaire (DTSQ) responses, and Short Form (36) Health Survey (SF-36) responses, were collected at baseline (T0) and at six months (T1). Results: Sixty-one subjects were enrolled, with there being an average T2D duration of 4.67 ± 3.93 years. Significant decreases were observed in HbA1c (µ = -1.24; SD = 1.33; p < 0.05), FPG (µ = -31.01 mg/dL; SD = 41.71; p < 0.05), body composition and anthropometric parameters (p < 0.05), and cardiovascular risk factors (p < 0.05), with an increase in DTSQ scores (p < 0.05). Conclusions: The administration of 14 mg/day oral semaglutide improved several clinical parameters after six months of treatment. These findings suggest semaglutide is effective in improving glycemic control, weight management, and some cardiovascular risk factors in T2D patients.

Keywords: body composition; obesity; oral semaglutide; real-world evidence; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chronological study flow chart.
Figure 2
Figure 2
General characteristics of the sample.
See this image and copyright information in PMC

References

    1. Ahmad E., Lim S., Lamptey R., Webb D.R., Davies M.J. Type 2 diabetes. Lancet. 2022;400:1803–1820. doi: 10.1016/S0140-6736(22)01655-5. - DOI - PubMed
    1. Magliano D.J., Boyko E.J. Idf Diabetes Atlas. Volume 2021 International Diabetes Feeration; Brussels, Belgium: 2021. Committee IDFDAtes. IDF diabetes atlas.
    1. Wong N.D., Sattar N. Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention. Nat. Rev. Cardiol. 2023;20:685–695. doi: 10.1038/s41569-023-00877-z. - DOI - PubMed
    1. Davies M.J., Aroda V.R., Collins B.S., Gabbay R.A., Green J., Maruthur N.M., Rosas S.E., Del Prato S., Mathieu C., Mingrone G., et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2022;45:2753–2786. doi: 10.2337/dci22-0034. - DOI - PMC - PubMed
    1. American Diabetes Association Professional Practice Committee. ElSayed N.A., Aleppo G., Bannuru R.R., Bruemmer D., Collins B.S., Ekhlaspour L., Gaglia J.L., Hilliard M.E., Johnson E.L., et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47((Suppl. S1)):S158–S178. doi: 10.2337/dc24-s009. - DOI - PMC - PubMed

LinkOut - more resources